Adult Spinal Cord Diffuse Midline Glioma, H3 K27-altered Mimics Symptoms of Central Nervous System Infection: a Case Report

Overview

Journal Front Neurol

Specialty Neurology

Date 2023 Jul 3

PMID 37396765

Authors

Xue Chen

Yi Li

Hui Bu

Yueli Zou

Junying He

Hu Liu

Affiliations

Soon will be listed here.

Abstract

Diffuse midline gliomas, H3 K27-altered are infiltrative growth gliomas with histone H3K27M mutations. This glioma is more common in the pediatric population, and the prognosis is usually poor. We report a case of diffuse midline gliomas, H3 K27-altered in an adult patient that mimicked symptoms of central nervous system infection. The patient was admitted due to double vision for 2 months and paroxysmal unconsciousness for 6 days. Initially, lumbar puncture showed persistent high intracranial pressure, high protein, and low chlorine. Magnetic resonance imaging showed diffuse thickening and enhancement of meninges and spinal meninges, and later, fever occurred. The initial diagnosis was meningitis. We suspected central nervous system infection, so we started anti-infection treatment, but the treatment was ineffective. The patient's condition gradually worsened, with lower limb weakness and even the consciousness became unclear. A repeat magnetic resonance imaging and positron emission tomography-computed tomography scan showed space-occupying lesions in the spinal cord, which was considered a tumor. Following neurosurgery, pathological tests identified the tumor as diffuse midline gliomas, H3 K27-altered. The patient was recommended for radiotherapy and temozolomide chemotherapy. The patient's condition improved after chemotherapy treatment, and he survived for an additional 6 months. Our case shows that diagnosing diffuse midline gliomas, H3 K27-altered in the central nervous system is complex and can be confused with the clinical characteristics of central nervous system infection. Therefore, clinicians should pay attention to such diseases to avoid misdiagnosis.

Citing Articles

Clinico-Pathological Features of Diffuse Midline Glioma, H3 K27-Altered in Adults: A Comprehensive Review of the Literature with an Additional Single-Institution Case Series.

Broggi G, Salzano S, Failla M, Barbagallo G, Certo F, Zanelli M Diagnostics (Basel). 2024; 14(23).

PMID: 39682526 PMC: 11640674. DOI: 10.3390/diagnostics14232617.

Positive H3K27M cytology in cerebrospinal fluid in diffuse midline glioma.

Kawai H, Hattori T, Nakajima Y, Yokota T, Onishi I Neurol Sci. 2024; 46(3):1451-1453.

PMID: 39546085 DOI: 10.1007/s10072-024-07839-4.

Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.

Zhao Z, Song Z, Wang Z, Zhang F, Ding Z, Fan T Technol Cancer Res Treat. 2024; 23:15330338241262483.

PMID: 39043042 PMC: 11271101. DOI: 10.1177/15330338241262483.

H3-Altered Diffuse Glioma of the Spinal Cord in Adult Patients: A Qualitative Systematic Review and Peculiarity of Radiological Findings.

Auricchio A, Pennisi G, Menna G, Olivi A, Gessi M, Gielen G J Clin Med. 2024; 13(10).

PMID: 38792513 PMC: 11122636. DOI: 10.3390/jcm13102972.

References

Zou Y, He J, Guo L, Bu H, Liu Y . Prediction of cerebrospinal fluid parameters for tuberculous meningitis. Diagn Cytopathol. 2015; 43(9):701-4. DOI: 10.1002/dc.23284. View

Lin A, Cheng B, Han X, Zhang H, Liu X, Liu X . Value of next-generation sequencing in early diagnosis of patients with tuberculous meningitis. J Neurol Sci. 2021; 422:117310. DOI: 10.1016/j.jns.2021.117310. View

Einstein E, Bonda D, Hosseini H, Harel A, Palmer J, Giglio P . Large Adult Spinal Diffuse Midline Histone H3 Lysine27-to-Methionine-Mutant Glioma With Intramedullary and Extramedullary Components Presenting With Progressive Hydrocephalus: A Case Report Highlighting Unique Imaging Findings and Treatment. Cureus. 2021; 13(5):e15333. PMC: 8240764. DOI: 10.7759/cureus.15333. View

Seong M, Kim S, Noh J, Kim Y, Kim H . Radiologic findings and the molecular expression profile of diffuse midline glioma H3 K27M mutant. Acta Radiol. 2020; 62(10):1404-1411. DOI: 10.1177/0284185120968560. View

Argersinger D, Rivas S, Shah A, Jackson S, Heiss J . New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of H3K27M-Mutant Diffuse Midline Glioma. Cancers (Basel). 2021; 13(21). PMC: 8582453. DOI: 10.3390/cancers13215280. View

Day C, Hinchcliffe E, Robinson J . H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes. Cells. 2022; 11(21). PMC: 9655269. DOI: 10.3390/cells11213376. View

Schulte J, Buerki R, LaPointe S, Molinaro A, Zhang Y, Villanueva-Meyer J . Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults. Neurooncol Adv. 2020; 2(1):vdaa142. PMC: 7739048. DOI: 10.1093/noajnl/vdaa142. View

Di Ruscio V, Del Baldo G, Fabozzi F, Vinci M, Cacchione A, de Billy E . Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle. Diagnostics (Basel). 2022; 12(9). PMC: 9497626. DOI: 10.3390/diagnostics12092064. View

Cantor E, Wierzbicki K, Tarapore R, Ravi K, Thomas C, Cartaxo R . Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022; 24(8):1366-1374. PMC: 9340643. DOI: 10.1093/neuonc/noac030. View

10.

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

11.

Schaller M, Wicke F, Foerch C, Weidauer S . Central Nervous System Tuberculosis : Etiology, Clinical Manifestations and Neuroradiological Features. Clin Neuroradiol. 2018; 29(1):3-18. DOI: 10.1007/s00062-018-0726-9. View

12.

Jones C, Karajannis M, Jones D, Kieran M, Monje M, Baker S . Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro Oncol. 2016; 19(2):153-161. PMC: 5464243. DOI: 10.1093/neuonc/now101. View

13.

Bahr N, Boulware D . Methods of rapid diagnosis for the etiology of meningitis in adults. Biomark Med. 2014; 8(9):1085-103. PMC: 4239990. DOI: 10.2217/bmm.14.67. View

14.

Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M . Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma. Curr Oncol Rep. 2020; 22(2):19. PMC: 7501595. DOI: 10.1007/s11912-020-0877-0. View

15.

Schreck K, Ranjan S, Skorupan N, Bettegowda C, Eberhart C, Ames H . Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas. J Neurooncol. 2019; 143(1):87-93. PMC: 6482123. DOI: 10.1007/s11060-019-03134-x. View

16.

Dono A, Takayasu T, Ballester L, Esquenazi Y . Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics. J Clin Neurosci. 2020; 82(Pt A):1-8. PMC: 7748263. DOI: 10.1016/j.jocn.2020.10.005. View

17.

Wang S, Chen Y, Wang D, Wu Y, Zhao D, Zhang J . The Feasibility of Metagenomic Next-Generation Sequencing to Identify Pathogens Causing Tuberculous Meningitis in Cerebrospinal Fluid. Front Microbiol. 2019; 10:1993. PMC: 6733977. DOI: 10.3389/fmicb.2019.01993. View

18.

Aboian M, Tong E, Solomon D, Kline C, Gautam A, Vardapetyan A . Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. AJNR Am J Neuroradiol. 2019; 40(11):1804-1810. PMC: 6907069. DOI: 10.3174/ajnr.A6302. View

19.

Heravi Shargh V, Luckett J, Bouzinab K, Paisey S, Turyanska L, Singleton W . Chemosensitization of Temozolomide-Resistant Pediatric Diffuse Midline Glioma Using Potent Nanoencapsulated Forms of a N(3)-Propargyl Analogue. ACS Appl Mater Interfaces. 2021; 13(30):35266-35280. DOI: 10.1021/acsami.1c04164. View

20.

Champeaux C, Drier A, Devaux B, Tauziede-Espariat A . Malignant primary diffuse leptomeningeal gliomatosis with histone H3.3 K27M mutation. Neurochirurgie. 2018; 64(3):198-202. DOI: 10.1016/j.neuchi.2017.12.007. View